Editas wins Australian clearance to start Phase 1/2 EDIT-401 trial in HeFH patients
EDIT•Editas Medicine received Australian ethics clearance to begin dosing in a Phase 1/2 trial of EDIT-401 in HeFH patients. First safety and tolerability data are expected in Q1 2027, with Part 1 topline safety and efficacy targeted for later in 2027.
1. Trial clearance and timing
Editas Medicine received Australian ethics clearance to start dosing in its Phase 1/2 EDIT-401 trial in HeFH patients and completed the TGA Clinical Trial Notification process. A New Zealand regulatory review is ongoing; first safety and tolerability data are expected in Q1 2027, and Part 1 topline safety and efficacy are targeted for later in 2027.
